<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548761" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548761/" /><meta name="ncbi_pagename" content="Belimumab - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Belimumab - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Belimumab" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/12/28" /><meta name="citation_pmid" content="31644070" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548761/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Belimumab" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/12/28" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548761/" /><meta name="description" content="Belimumab is a human monoclonal antibody to the soluble B-lymphocyte stimulator (BLsY) which is used in the therapy of systemic lupus erythematous. Belimumab has been linked to an uncommon incidence of transient serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent liver injury." /><meta name="og:title" content="Belimumab" /><meta name="og:type" content="book" /><meta name="og:description" content="Belimumab is a human monoclonal antibody to the soluble B-lymphocyte stimulator (BLsY) which is used in the therapy of systemic lupus erythematous. Belimumab has been linked to an uncommon incidence of transient serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548761/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Belimumab/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548761/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D1C91046642C100000000047A0140.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548761_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548761_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Bedaquiline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Belinostat/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548761_"><span class="title" itemprop="name">Belimumab</span></h1><p class="small">Last Update: <span itemprop="dateModified">December 28, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Belimumab.OVERVIEW"><h2 id="_Belimumab_OVERVIEW_">OVERVIEW</h2><div id="Belimumab.Introduction"><h3>Introduction</h3><p>Belimumab is a human monoclonal antibody to the soluble B-lymphocyte stimulator (BLsY) which is used in the therapy of systemic lupus erythematous. Belimumab has been linked to an uncommon incidence of transient serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent liver injury.</p></div><div id="Belimumab.Background"><h3>Background</h3><p>Belimumab (be lim&#x02019; ue mab) is a human monoclonal IgG1 antibody to the B-lymphocyte stimulator (BLyS, B cell activating factor), a growth factor required for B cell activation, survival, maturation into plasma cells and immunoglobulin production. Belimumab binds to soluble BLyS and blocks its binding to B cell receptors, which results in a depletion of activated B cells. This monoclonal antibody has been shown to be effective in reducing disease activity in patients with systemic lupus erythematosus, a disease marked by elevated levels of soluble BLyS, B cell dysregulation and production of pathogenic autoantibodies and immune complexes. Belimumab was approved for use in the United States in 2011 and current indications are for treatment of children (ages 5 years and above) and adult patients with active, autoantibody positive systemic lupus erythematosus (SLE) who are receiving standard therapy. It is also approved as therapy for lupus nephritis. Belimumab is available in two forms under the brand name Benlysta: as a lyophilized powder in 120 and 400 mg single dose vials for intravenous use in children or adults, or as a solution of 200 mg/mL a prefilled autoinjector or singe-dose syringe for subcutaneous use in adults only. For the intravenous formulation, the recommended dose is 10mg/kg every 2 weeks for 3 doses and then every 4 weeks. Premedication with an antihistamine is recommended. For the subcutaneous formulation, the dose is 200 mg once weekly. Adverse effects include infusion reactions, nausea, diarrhea, headache, insomnia, depression, pain in the extremities and low grade fever. Rare, but potentially serious side effects include anaphylactic reactions, serious infections, progressive multifocal leukoencephalopathy (PML), depression and suicide.</p></div><div id="Belimumab.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In publications on the large scale trials of belimumab, elevations in serum aminotransferase levels were uncommon (less than 1%) and no more frequent during belimumab therapy than in placebo treated controls. In the prelicensure studies there were no reports of clinically apparent liver injury attributed to belimumab and, since its approval and more wide scale use, there have been no case reports of liver injury with jaundice linked to belimumab therapy. Reactivation of hepatitis B can occur with use of immunosuppressive monoclonal antibodies such as infliximab and adalimumab, but instances have not been reported with belimumab. However, belimumab does result in a decrease in circulating B cells and immunoglobulin levels and thus might be a cause of reactivation of HBV replication in a susceptible patient. Nevertheless, severe liver injury has not been reported with use of belimumab.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Belimumab.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the rare serum enzyme elevations during belimumab therapy is not known. Monoclonal antibodies are generally metabolized to small peptides and amino acids by multiple tissues including the liver and are not intrinsically toxic to hepatocytes. Most clinically significant liver injury induced by monoclonal antibodies is due to induction of autoimmunity or reactivation of hepatitis B.</p></div><div id="Belimumab.Outcome_and_Management"><h3>Outcome and Management</h3><p>The serum aminotransferase elevations that have been reported during belimumab therapy were generally transient, mild and asymptomatic and did not require dose modification or delay in therapy. Elevations above 5 times the upper limit of normal should lead to more careful monitoring and suspension of further infusions, at least until levels return to normal or near normal levels. There is no evidence of cross sensitivity to hepatic reactions among the various monoclonal antibodies.</p><p>Drug Class: <a href="/books/n/livertox/MonoclonalAntibodies/">Monoclonal Antibodies</a>; Immunosuppressive Agents</p></div></div><div id="Belimumab.PRODUCT_INFORMATION"><h2 id="_Belimumab_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Belimumab &#x02013; Benlysta&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Immunosuppressive Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?label=all&#x00026;query=Belimumab" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Belimumab.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Belimumab_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Belimumab.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548761/table/Belimumab.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Belimumab.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Belimumab.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Belimumab.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_h_Belimumab.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Belimumab.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Belimumab.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Belimumab</td><td headers="hd_h_Belimumab.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135353783" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">356547-88-1</a></td><td headers="hd_h_Belimumab.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Monoclonal Antibody</td><td headers="hd_h_Belimumab.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Belimumab.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Belimumab_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 28 December 2020</p><p>Abbreviations: PML, progressive multifocal leukoencephalopathy; SLE, systemic lupus erythematosus.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Belimumab.REF.zimmerman.1999">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 517-54.<div><i>(Expert review of hepatotoxicity published in 1999, well before the availability of most antibody therapies).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.reuben.2011">Reuben A. Hepatotoxicity of immunosuppressive drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 569-91.<div><i>(Review of hepatotoxicity of immunosuppressive agents does not mention belimumab).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.krensky.2018">Krensky AM, Azzi JR, Hafler DA. Immunosuppressants and toleragens. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 637-53.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.furie.2008.r109">Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, et al. Belimumab Study Group.  Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. <span><span class="ref-journal">Arthritis Res Ther. </span>2008;<span class="ref-vol">10</span>:R109.</span> [<a href="/pmc/articles/PMC2592791/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2592791</span></a>] [<a href="/pubmed/18786258" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18786258</span></a>]<div><i>(Among 70 patients with systemic lupus erythematosus [SLE] given 1 to 2 infusions of 4 doses of belimumab or placebo, CD20+ B cells decreased, but indices of disease activity did not change; ALT elevations above 5 times ULN occurred in 1 of 57 belimumab vs none of 13 placebo recipients).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.wallace.2009.1168">Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, et al.  A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <span><span class="ref-journal">Arthritis Rheum. </span>2009;<span class="ref-vol">61</span>:1168–78.</span> [<a href="/pmc/articles/PMC2758229/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2758229</span></a>] [<a href="/pubmed/19714604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19714604</span></a>]<div><i>(Among 449 patients with SLE treated with 3 doses of belimumab or placebo for 52 weeks, rates of adverse events were similar except for urticarial [4% vs 0%], no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.jacobi.2010.201">Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, et al.  Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. <span><span class="ref-journal">Arthritis Rheum. </span>2010;<span class="ref-vol">62</span>:201–10.</span> [<a href="/pmc/articles/PMC2857977/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2857977</span></a>] [<a href="/pubmed/20039404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20039404</span></a>]<div><i>(Analysis of 17 patients treated with belimumab long term showed decreases in B cells and IgM levels, but not in T cells, IgG or anti-dsDNA levels).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.navarra.2011.721">Navarra SV, Guzm&#x000e1;n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, et al. BLISS-52 Study Group.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <span><span class="ref-journal">Lancet. </span>2011;<span class="ref-vol">377</span>(9767):721–31.</span> [<a href="/pubmed/21296403" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21296403</span></a>]<div><i>(Among 865 patients with SLE treated with two doses of belimumab or placebo for 52 weeks, adverse events were similar in the 3 groups; 3 patients developed anaphylactoid reactions; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.sanz.2011.335">Sanz I, Yasothan U, Kirkpatrick P. Belimumab. <span><span class="ref-journal">Nat Rev Drug Discov. </span>2011;<span class="ref-vol">10</span>:335–6.</span> [<a href="/pubmed/21532557" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21532557</span></a>]<div><i>(Short review of the development, mechanism of action, efficacy, safety and market value of belimumab).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.furie.2011.3918">Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov&#x000e1; D, Sanchez-Guerrero J, et al. BLISS-76 Study Group.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <span><span class="ref-journal">Arthritis Rheum. </span>2011;<span class="ref-vol">63</span>:3918–30.</span> [<a href="/pmc/articles/PMC5007058/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5007058</span></a>] [<a href="/pubmed/22127708" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22127708</span></a>]<div><i>(Among 819 patients with SLE treated with one of two doses of belimumab or placebo for 52 weeks, a higher proportion of those treated with 10 mg/kg met the response criteria at week 52 [43%] than those treated with 1 mg/kg [41%] or placebo [34%], while rates of most adverse events were similar and ALT elevations were not mentioned; infusions reactions and depression were more frequent with belimumab).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF10">Belimumab (Benlysta) for systemic lupus erythematosus. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2011;<span class="ref-vol">53</span>(1366):45–6.</span> [<a href="/pubmed/21659968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21659968</span></a>]<div><i>(Concise summary of the mechanism of action, efficacy, safety and costs of belimumab for SLE mentions that belimumab can modestly reduce disease activity, and common side effects are infusion reactions, nausea, diarrhea and fever; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.gamble.2012.376">Gamble RG, Dellavalle RP. A randomized controlled trial of belimumab for the treatment of active systemic lupus erythematosus. <span><span class="ref-journal">Arch Dermatol. </span>2012;<span class="ref-vol">148</span>:376–8.</span> [<a href="/pubmed/22431778" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22431778</span></a>]<div><i>(Commentary on Navarra [2011]).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.merrill.2012.3364">Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, et al. LBSL02/99 Study Group.  Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <span><span class="ref-journal">Arthritis Rheum. </span>2012;<span class="ref-vol">64</span>:3364–73.</span> [<a href="/pubmed/22674457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22674457</span></a>]<div><i>(Analysis of 1165 patient years of exposure to belimumab during the first 4 years of treatment, states that infusion reactions occurred only during the first year of treatment and that liver test abnormalities [&#x02265;grade 3] occurred in &#x0003c;2% of patients and did not increase over time).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.manzi.2012.1833">Manzi S, S&#x000e1;nchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, et al. BLISS-52 and BLISS-76 Study Groups.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. <span><span class="ref-journal">Ann Rheum Dis. </span>2012;<span class="ref-vol">71</span>:1833–8.</span> [<a href="/pmc/articles/PMC3465857/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3465857</span></a>] [<a href="/pubmed/22550315" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22550315</span></a>]<div><i>(Combined analysis of trials reported by Furie [2011] and Navarra [2011]).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.wallace.2013.144">Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, et al.  BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. <span><span class="ref-journal">Lupus. </span>2013;<span class="ref-vol">22</span>:144–54.</span> [<a href="/pubmed/23213069" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23213069</span></a>]<div><i>(Pooled data on safety from 3 large trials of belimumab in patients with SLE found similar rates of serious infusion reactions, serious infections and malignancies in placebo vs belimumab treated subjects; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.hahn.2013.1528">Hahn BH. Belimumab for systemic lupus erythematosus. <span><span class="ref-journal">N Engl J Med. </span>2013;<span class="ref-vol">368</span>:1528–35.</span> [<a href="/pubmed/23594005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23594005</span></a>]<div><i>(Review of the clinical features and pathogenesis of SLE and the mechanism of action, efficacy and safety of belimumab in its treatment; in combined studies, responses occurred in 51% of belimumab vs 39% of placebo recipients; adverse events include infusion reactions, depression of serious infections; no mention of ALT elevations of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.stohl.2013.579">Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. <span><span class="ref-journal">J Rheumatol. </span>2013;<span class="ref-vol">40</span>:579–89.</span> [<a href="/pubmed/23547209" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23547209</span></a>]<div><i>(Among 283 patients with active rheumatoid arthritis treated with one of 3 doses of belimumab or placebo for 24 weeks followed by an open label 24 week extension, responses were higher at 24 weeks with belimumab [29% vs 16%] and adverse events, that were more frequent with belimumab, included infusion reactions [13% vs 6%], but ALT elevations were not mentioned).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.askanase.2014.507">Askanase AD, Yazdany J, Molta CT. Post-marketing experiences with belimumab in the treatment of SLE patients. <span><span class="ref-journal">Rheum Dis Clin North Am. </span>2014;<span class="ref-vol">40</span>:507–17.</span> [<a href="/pubmed/25034159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25034159</span></a>]<div><i>(Analysis of 3 postmarketing observational studies of belimumab focusing largely on efficacy; "No new safety signals were noted with regards to infections, malignancies, depression or deaths").</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.fredericks.2014.711">Fredericks CA, Kvam KA, Bear J, Crabtree GS, Josephson SA. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. <span><span class="ref-journal">Lupus. </span>2014;<span class="ref-vol">23</span>:711–3.</span> [<a href="/pubmed/24531080" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24531080</span></a>]<div><i>(40 year old woman with SLE developed neurological decline 10 months after starting belimumab infusions [while on mycophenolate mofetil and prednisone as well], with JC viral DNA detected in cerebral spinal fluid, a progressive downhill course and death within 6 months).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.sthoeger.2017.44">Sthoeger Z, Lorber M, Tal Y, Toubi E, Amital H, Kivity S, Langevitz P, et al.  Anti-BLyS treatment of 36 Israeli systemic lupus erythematosus patients. <span><span class="ref-journal">Isr Med Assoc J. </span>2017;<span class="ref-vol">19</span>:44–8.</span> [<a href="/pubmed/28457114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28457114</span></a>]<div><i>(Among 36 adults with SLE treated with belimumab for at least one year, it "was well tolerated without significant adverse events").</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.ginzler.2014.300">Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, et al. LBSL02/99 Study Group.  Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. <span><span class="ref-journal">J Rheumatol. </span>2014;<span class="ref-vol">41</span>:300–9.</span> [<a href="/pubmed/24187095" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24187095</span></a>]<div><i>(Among 449 patients with SLE treated with belimumab for up to 7 years, adverse events were reported as being stable and decreasing in frequency over time; no mention of ALT elevations, hepatotoxicity or deaths from liver disease).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.henegar.2016.617">Henegar CE, Eudy AM, Kharat V, Hill DD, Bennett D, Haight B. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. <span><span class="ref-journal">Lupus. </span>2016;<span class="ref-vol">25</span>:617–26.</span> [<a href="/pubmed/26743322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26743322</span></a>]<div><i>(Systematic review of the literature identified 35 cases of PML reported in patients with SLE, 3 of whom were on no immunosuppressive medications, but possibly implicated drugs included corticosteroids, cyclophosphamide, mycophenolate, azathioprine and rituximab [n=5], while only one had received belimumab).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.stohl.2017.1016">Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, et al.  Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. <span><span class="ref-journal">Arthritis Rheumatol. </span>2017;<span class="ref-vol">69</span>:1016–27.</span> [<a href="/pmc/articles/PMC5434872/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5434872</span></a>] [<a href="/pubmed/28118533" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28118533</span></a>]<div><i>(Among 836 patients with SLE treated with intravenous belimumab or placebo for 52 weeks, response rates were higher with belimumab while adverse events were similar; injection site reactions occurred in 6% vs 2%; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.furie.2018.868">Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, et al.  Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States. <span><span class="ref-journal">Arthritis Rheumatol. </span>2018;<span class="ref-vol">70</span>:868–77.</span> [<a href="/pmc/articles/PMC6001779/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6001779</span></a>] [<a href="/pubmed/29409143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29409143</span></a>]<div><i>(Among 268 patients with SLE enrolled in a long term extension trial of intravenous belimumab for up to 7 years, response rates continued to increase, and mean corticosteroid dosage decreased; while adverse events were mostly mild-to-moderate arthralgias, nausea, headache and infections, there were no deaths that were drug related and no mention of ALT elevations or hepatotoxicity; 10% of patients discontinued therapy because of adverse events).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.van_vollenhoven.2020.281">van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, et al.  Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. <span><span class="ref-journal">Rheumatology (Oxford). </span>2020;<span class="ref-vol">59</span>:281–91.</span> [<a href="/pmc/articles/PMC7571485/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7571485</span></a>] [<a href="/pubmed/31302695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31302695</span></a>]<div><i>(Among 738 patients with SLE entered into an open-label extension trial after two 1-year randomized controlled trials of intravenous belimumab, adverse events decreased or remained stable over time and no deaths were attributed to drug toxicity; ALT elevations above 5 times ULN occurred in &#x0003c;1% of patients during the first 4 years and in none during the subsequent follow up period; no mention of hepatotoxicity, HBV reactivation or liver related severe adverse events).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.brunner.2020.1340">Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, et al. Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).  Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <span><span class="ref-journal">Ann Rheum Dis. </span>2020;<span class="ref-vol">79</span>:1340–8.</span> [<a href="/pmc/articles/PMC7509523/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7509523</span></a>] [<a href="/pubmed/32699034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32699034</span></a>]<div><i>(Among 93 children with SLE treated with belimumab or placebo infusions every 4 weeks for 52 weeks, clinical responses were more frequent with belimumab [53% vs 44%] while adverse event rates were similar [79% vs 83%], although serious adverse event rates were less [17% vs 35%], and one patient on belimumab discontinued therapy because of aminotransferase elevations).</i></div></div></li><li><div class="bk_ref" id="Belimumab.REF.furie.2020.1117">Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, et al.  Two-year, randomized, controlled trial of belimumab in lupus nephritis. <span><span class="ref-journal">N Engl J Med. </span>2020;<span class="ref-vol">383</span>:1117–28.</span> [<a href="/pubmed/32937045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32937045</span></a>]<div><i>(Among 448 patients with lupus nephritis treated with intravenous belimumab of placebo for 2 years, a primary renal response was more frequent with belimumab [43% vs 32%], while overall and serious adverse event rates were similar between the two groups including herpes zoster [6% vs 4%], opportunistic infections [13% vs 15%], serious infections [4% vs 3%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548761</span><span class="label">PMID: <a href="/pubmed/31644070" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644070</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Bedaquiline/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Belinostat/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548761&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548761/?report=reader">PubReader</a></li><li><a href="/books/NBK548761/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548761" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548761" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Belimumab. [Updated 2020 Dec 28].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548761/pdf/Bookshelf_NBK548761.pdf">PDF version of this page</a> (100K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Belimumab+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Belimumab: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Belimumab" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Belimumab: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4860308" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4860308" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4860308" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18457473" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.</a><span class="source">[Drugs R D. 2008]</span><div class="brieflinkpop offscreen_noflow">Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs R D. 2008; 9(3):197-202. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18786258" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.</a><span class="source">[Arthritis Res Ther. 2008]</span><div class="brieflinkpop offscreen_noflow">Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arthritis Res Ther. 2008; 10(5):R109. Epub 2008 Sep 11.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22127708" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.</a><span class="source">[Arthritis Rheum. 2011]</span><div class="brieflinkpop offscreen_noflow">A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arthritis Rheum. 2011 Dec; 63(12):3918-30. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22141386" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Belimumab: in systemic lupus erythematosus.</a><span class="source">[Drugs. 2011]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Belimumab: in systemic lupus erythematosus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Burness CB, McCormack PL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2011 Dec 24; 71(18):2435-44. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29396833" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Belimumab: A Review in Systemic Lupus Erythematosus.</a><span class="source">[Drugs. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Belimumab: A Review in Systemic Lupus Erythematosus.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Blair HA, Duggan ST. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2018 Mar; 78(3):355-366. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644070" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644070" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604678db0831bd46661f4d44">Belimumab - LiverTox</a><div class="ralinkpop offscreen_noflow">Belimumab - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:19:56-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D1C91046642C100000000047A0140&amp;ncbi_session=CE8D1C9104678DB1_1146SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548761%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548761&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548761/&amp;ncbi_pagename=Belimumab - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D1C9104678DB1_1146SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>